Eli Lilly & (LLY) Stock
Major pharmaceutical group with diabetes and obesity medicines. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in July 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Eli Lilly stays in favor as analysts back its growth runway and 2026 outlook.
- Wall Street’s consensus remains constructive on Eli Lilly, with analysts broadly still assigning a Buy stance, reinforcing expectations that the stock’s longer-term growth story is intact.
- The average price targets cluster around the low-to-mid $1,200s, suggesting investors are still pricing in meaningful upside from current levels despite the stock’s already elevated valuation.
- Recent commentary has continued to point to Lilly’s strong 2026 outlook, with analysts citing robust operating momentum and confidence in the company’s growth pipeline as key support for sentiment.
Eli Lilly stays in favor as analysts back its growth runway and 2026 outlook.
- Wall Street’s consensus remains constructive on Eli Lilly, with analysts broadly still assigning a Buy stance, reinforcing expectations that the stock’s longer-term growth story is intact.
- The average price targets cluster around the low-to-mid $1,200s, suggesting investors are still pricing in meaningful upside from current levels despite the stock’s already elevated valuation.
- Recent commentary has continued to point to Lilly’s strong 2026 outlook, with analysts citing robust operating momentum and confidence in the company’s growth pipeline as key support for sentiment.
When is the next earnings date for Eli Lilly & Co (LLY)?
The next earnings date for LLY is expected on August 5, 2026 or August 6, 2026, depending on the source, with the most common estimates pointing to August 5, 2026. It will cover Q2 2026 results. For a precise investor calendar, this timing is consistent with Eli Lilly’s typical early-August earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Eli Lilly's stock, expecting its value to grow from current levels.
Financial Health
Eli Lilly is performing exceptionally well with strong profits, high revenue, and solid cash flow.
Dividend
Eli Lilly's low dividend yield of 0.52% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $5.23 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring LLY
The GLP-1 Insurance Gap Reshaping Weight Care in 2026
Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published: 3 June 2026
Explore BasketAI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketUS Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketCould Dermatology Biologics Unlock Predictable Revenue?
Eli Lilly's eczema drug EBGLYSS has demonstrated sustained, multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies. This clinical milestone validates the broader dermatology market, creating opportunities for biopharmaceutical companies developing innovative skin treatments.
Published: 28 March 2026
Explore BasketInvestment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketAI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: 13 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Compare Eli Lilly with other stocks
Eli Lilly vs Novo Nordisk
Eli Lilly vs Novo Nordisk: A Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
